home / stock / cing / cing news

CING News and Press, Cingulate Inc. From 11/03/22

Stock Information
Company Name: Cingulate Inc.
Stock Symbol: CING
Market: NASDAQ
Website: cingulate.com
Menu
CING CING Quote CING Short CING News CING Articles CING Message Board
Get CING Alerts

News, Short Squeeze, Breakout and More Instantly...
CING - Cingulate Inc. to Present at Investor Summit Group's Q4 Conference

Kansas City, Kansas--(Newsfile Corp. - November 3, 2022) - Cingulate Inc. (NASDAQ: CING) , a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical pr...
CING - Cingulate Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead Candidate for Treatment of ADHD

KANSAS CITY, Kan., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical product...

CING - Cingulate Announces Agreement with Societal CDMO and Provides Clinical Update

KANSAS CITY, Kan., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical product...

CING - Cingulate to Present at LD Micro Investor Conference

KANSAS CITY, Kan., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical product...
CING - Cingulate Presents Data for Its Triple-Release Buspirone Product Candidate: CTx-2103

Data Demonstrated Ability of CTx-2103 to Deliver a Single Administration of Triple-Release Buspirone – Setting the Stage for Future Trials Employing Cingulate’s Precision Timed Release™ (PTR™) Technology CTx-2103 has the Potential to be the First Once...

CING - Cingulate to Participate in Benzinga All Live Access Event

KANSAS CITY, Kan., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmac...

CING - Cingulate Q2 GAAP EPS of -$0.36

Cingulate press release ( NASDAQ: CING ): Q2 GAAP EPS of -$0.36. As of Jun. 30, Cingulate had $8.2M in cash and cash equivalents. Shares +19.39% PM. For further details see: Cingulate Q2 GAAP EPS of -$0.36

CING - Kansas City Business Journal Names Cingulate's Louis G. Van Horn a 2022 Chief Financial Officer of the Year

KANSAS CITY, Kan., July 25, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmac...

CING - SOS, XELA and MGNX among mid-day movers

Gainers: Qudian ( QD ) +48% . Marathon Digital ( MARA ) +32% . SQL Technologies ( SKYX ) +27% . SOS ( SOS ) +25% . Hut 8 Mining ( HUT ) +24% . North European Oil Royalty Trust ( NRT ) +24% . Advent Technologies ( ...

CING - Cingulate Announces Completion of CTx-2103 Human Formulation Study for the Treatment of Anxiety Disorders

KANSAS CITY, Kan., June 23, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmac...
Previous 10 Next 10